IRVINE, Calif., Oct. 4 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI), a biotechnology company focused on the development of innovative cancer therapies, announced today that Timothy P. Walbert, president and chief executive officer, will present a corporate overview at the BIO InvestorForum in San Francisco on Thursday, October 11, 2007 at 1 p.m. PDT at the Palace Hotel.
A webcast of the presentation will be available live and following the presentation at http://www.idm-pharma.com.
About IDM Pharma
IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.
For more information about the company and its products, visit http://www.idm-pharma.com.
The presentation described in this press release will include
forward-looking statements that reflect management's current views of
future events including statements regarding the Company's plans to
collect, analyze and submit additional Phase 3 data in an amended NDA for
L-MTP-PE and to respond to other matters raised by ODAC and the FDA, the
Company's confidence that the proposed NDA amendment will provide
substantial evidence for the continued regulatory approval process, the
review of the submissions for marketing approval of L-MTP-PE by the FDA
|SOURCE IDM Pharma, Inc.|
Copyright©2007 PR Newswire.
All rights reserved